Tessa Therapeutics Announces Acquisition of Euchloe Bio
Tessa Therapeutics, an immunotherapy company dedicated to revolutionising the treatment of cancer, has acquired Euchloe Bio, a biotechnology company specialising in the development and commercialisation of antibodies to treat cancer.
The combination of the technologies and research & development capabilities of the two companies will enhance and widen the application of their cellular immunotherapies to treat a broader range of cancer indications.
Read the full press release here.
Mewburn Ellis partners Richard Clegg, Frances Salisbury and associate Adam Gregory work closely with Tessa Therapeutics and Euchloe Bio in relation to the building and defending of their IP portfolios.